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Abstract
Background: Many control methods have been implemented to tackle onchocerciasis and great successes have
been achieved, leading to a paradigm shift from control of morbidity to interruption of transmission and ultimately
elimination. The mandate of the African Programme for Onchocerciasis Control (APOC) ended in 2015, and endemic
countries are to plan and conduct elimination activities by themselves, with technical assistance by the Expanded
Special Project for Elimination of Neglected Tropical Diseases (ESPEN). To this end, an elimination expert committee
was set up in Cameroon in 2018. This committee identified the need to update the data on the current situation of
onchocerciasis. The present study aims to systematically review and report all available epidemiological data, including
prevalence, intensity and transmission of onchocerciasis to provide pertinent information that will be useful to design
optimal strategies to achieve onchocerciasis elimination in Cameroon.
Methods: PubMed/MEDLINE, EMBASE and Web of Science will be searched from inception onwards. Grey literature
will be identified through Google Scholar searches, dissertation databases and other relevant documents such as
government reports. Eligible studies will be mostly observational, including cohort and cross-sectional surveys. No
limitations will be imposed on publication status and study period. The primary outcomes will be (1) the prevalence
and intensity of Onchocerca volvulus infection in humans, (2) transmission intensity and (3) impact of interventions on
prevalence, intensity and transmission of onchocerciasis. Secondary outcomes will be environmental and socio-
demographic factors supporting the primary outcomes. Two reviewers will independently screen all citations, full-text
articles and abstract data. Potential conflicts will be resolved through discussion. Methodological quality including bias
will be appraised using appropriate approaches. A narrative synthesis will describe quality and content of the
epidemiological evidence. Prevalence and intensity of infection estimates will be stratified according to gender, age,
geographical location and year of publication.
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Discussion: This study will provide the health authorities as well as the scientific community with up-to-date
information about the epidemiological situation of onchocerciasis in Cameroon. Understanding the
spatiotemporal dynamics of the infection will help to define alternative and complementary strategies to
accelerate onchocerciasis elimination in the country. Results of this review will also be used to update
existing epidemiological models for onchocerciasis in order to fine-tune predictions of elimination timeframes
in the country.
Systematic review registration: This protocol is under registration review in PROSPERO.
Keywords: Onchocerciasis, Elimination, Cameroon, Systematic review, Protocol
Introduction
Rationale
The paradigm of the fight against onchocerciasis has shifted
from morbidity control to interruption of transmission and
ultimately elimination since 2010 in Africa [1], motivated
by the demonstration in some foci that onchocerciasis can
be eliminated by long-term annual (or biannual) mass drug
administration (MDA) of ivermectin [2–4]. Despite this en-
thusiastic and optimistic declaration and commitment by
control programmes and stakeholders, the truth is that the
infection still persists in many endemic foci in Africa [5, 6].
A previous study documenting epidemiological trends
mainly in the countries of the former Onchocerciasis Con-
trol Programme in West Africa (OCP) area indicated that
ivermectin alone would not help achieving onchocerciasis
elimination in some foci before 2030 [7]. Mathematical
modelling has also indicated that in the most highly en-
demic foci, ivermectin alone will not be sufficient to elimin-
ate the infection [8, 9]. It is now unanimously accepted that
alternative and complementary treatment strategies (ATS)
will certainly be necessary in some epidemiological settings
[10], and Boussinesq and colleagues have provided detailed
information on the different options to be considered to ac-
celerate onchocerciasis elimination [11]. Therefore, an es-
sential step to be taken is the situation analysis of
onchocerciasis in each endemic country to identify the ap-
propriate suite of interventions that need to be imple-
mented to achieve interruption of transmission, if not by
2020 (the year proposed by the World Health Organization
(WHO) in its 2012 roadmap on neglected tropical diseases
[12], by 2025 (when 80% of African endemic countries
should achieve elimination as suggested by the Joint Action
Forum of the WHO/African Programme for Onchocercia-
sis Control (APOC) (JAF 2012, Final Communiqué).
Cameroon in particular is a country with great ecological
and epidemiological diversity, not only for onchocerciasis
but also for other filarial infections that make it difficult to
implement ivermectin MDA. This study is a systematic re-
view aiming to collate all existing data on onchocerciasis
epidemiology in relation to the interventions that have been
implemented and the environmental determinants of its
transmission in Cameroon.
Objectives
The main objective of this systematic review will be to
report spatiotemporal trends in prevalence, intensity and
transmission of Onchocerca volvulus infection in Cameroon.
The secondary objective will consist in collating interven-
tions and socio-demographic and environmental data in
order to elucidate their impact on prevalence, intensity of
infection and transmission of onchocerciasis in Cameroon.
The goal is to provide the NOCP and the national com-
mittee for elimination of onchocerciasis and lymphatic fil-
ariasis (NCEOLF) with robust and reliable data that can
be analysed to make informed decisions on context-
specific current or alternative treatment strategies that
need to be implemented to achieve the WHO/APOC goal
of onchocerciasis elimination by 2025 and beyond.
The study therefore intends to address the following
questions:
1. What are the trends in prevalence, intensity of
infection and transmission of onchocerciasis in
Cameroon from baseline and following the
inception of interventions onwards?
2. What is the impact of different control
interventions on infection prevalence, intensity and
transmission of onchocerciasis in Cameroon?
3. What are the potential factors underlying the
trends in prevalence, intensity of infection and
transmission of onchocerciasis in Cameroon?
Methods
This review protocol was reported in accordance with
reporting guidance provided by the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses Proto-
cols (PRISMA-P) statement [13] (see PRISMA-P checklist
in Additional file 1). In addition, the process of registering
the review protocol with the PROSPERO database was ini-
tiated (registration reference number: 158962; registration
process ongoing in PROSPERO).
Eligibility criteria
No restrictions will be made on the time horizon of the
studies. In contrast, any cohort or cross-sectional study,
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either published or unpublished, assessing the endem-
icity of Onchocerca volvulus infection (prevalence and/or
intensity or transmission), as well as the interventions
used to control this filarial disease in Cameroon, will be
eligible for this systematic review. Studies involving ei-
ther blackfly vector (Simulium spp.) or human popula-
tion whatever their age and gender will be targeted.
However, case reports, clinical trials, editorials, letters to
the editor, systematic reviews or meta-analyses will be
excluded. Search languages will be limited to French and
English, the Cameroon official languages in which al-
most all publications are done.
Information sources and search strategy
PubMed/MEDLINE, EMBASE and Web of Science will be
searched, from their inception onwards, to identify relevant
articles [14, 15]. Grey literature will be identified through
search in Google Scholar and other relevant documents
such as dissertation databases and government reports. The
combination of keywords to use in the search strategy will
be “cécité des rivières” OR “onchocercose” OR “onchocer-
ciasis” OR “river blindness” OR “onchocerca volvulus” OR
“simulium” OR “simulie” OR “blackflies” AND “cameroun”
OR “cameroon”. A draft search strategy in PubMed/MED-
LINE is available in Additional file 2. The reference lists of
examined full-text papers will be scrutinized for additional
relevant articles. Authors of primary publications or aggre-
gated data and stakeholders involved in research and/or
control of onchocerciasis in Cameroon (National Oncho-
cerciasis Control Programme (NOCP) and NGDOs) will be
contacted to request for unpublished data and/or resources
(reports, datasets) relevant for this study.
Study selection
The web-based software platform Covidence (www.covi
dence.org) will be used to manage the records obtained
with the search strategy (citation screening, full-text review,
risk of bias assessment, extraction of study characteristics
and outcomes, export of data and references … ). In
addition, two investigators will independently screen the
studies identified by the searches following a two-step pro-
cedure. The first step will consist in the screening of titles
and abstracts for relevance and exclusion of published
literature that does not fulfil the eligibility criteria. The sec-
ond step will consist in the review of full texts of potentially
relevant and completely relevant literature identified during
first screening step to assess their eligibility. In case of dis-
agreements, a third investigator will be involved as an adju-
dicator, either by consensus or by discussion.
Data extraction and management
Data will be extracted onto an Excel spreadsheet contain-
ing relevant information for the objective of the systematic
review (see data items below). This will be performed by
two independent reviewers, and any disagreements will be
resolved by a third reviewer. When data will not be avail-
able (or unclear) in the manuscripts, the authors of the
studies may be contacted for clarification.
Data curation
Prior to data extraction per se, a reference manager soft-
ware (EndNote/Zotero) will be used to manage the retrieval
of literature and to screen for and exclude duplicates. This
will be done first automatically using the “find duplicate” or
“de-duplication” function under EndNote or Zotero, re-
spectively, by comparing the title or various combinations
of the author(s), year, secondary title, volume, issue and
page numbers. In the second instance, the records of sus-
pected duplicates will be visually inspected.
Data items
After curation of the database, the full texts of the studies
adhering to all the above eligibility criteria will be read,
and a Microsoft Excel spreadsheet will be used for data
extraction. The following items will be extracted: (1) pub-
lication title, (2) year of publication, (3) year(s) of data col-
lection, (4) authors’ names, (5) location of the study
(region, health district, community), (6) geographical
coordinates (latitude and longitude) and altitude, (7) type
of environment (forest, savannah, forest-savannah mosaic,
type of vegetation), (8) climate data (temperature, precipi-
tation, humidity), (9) river basin and proximity of study lo-
cation to rivers/vector breeding sites, (10) intervention
information (MDA, drug used for MDA, number of treat-
ment rounds, duration of treatment, frequency, time inter-
val between treatment and parasitological assessment,
geographic coverage, minimum and maximum therapeutic
coverage, treatment adherence, vector control, method for
vector control), (11) human sample size, (12) age (and
sex) of enrollees (maximal, minimal and median age (for
males and females if available)), (13) assessment tool (skin
snips for assessment of microfilaridermia with details on
type of punch, incubation medium, incubation time, enu-
meration of microfilariae, weight of snips; nodule palpa-
tion; serological assay), (14) nodule data (prevalence,
minimum, maximum and mean number of nodules), (15)
skin snip data (microfilarial prevalence, minimum, max-
imum and mean number of microfilariae per skin snip or
per milligrams of skin, community microfilarial load
(CMFL)), (16) serological data (age groups tested, antigen
used, seroprevalence), (17) blackfly data (sample size; bit-
ing rate; diagnostic tool for detection of infection in black-
flies; number of flies with L1, L2 and L3; number of L3
per fly; minimum, maximum and mean number of L3 in
the head/body), (18) vector identification and method
(morphotaxonomy, cytotaxonomy, other), vector spe-
cies composition, vector bionomics, as well as (19)
co-endemicity with loiasis.
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Outcomes and prioritization
The primary outcomes will be (1) the prevalence and inten-
sity of Onchocerca volvulus infection in humans (measured
by microfilaridermia and palpable nodule data), (2) trans-
mission intensity [measured by entomological indices such
as vector biting rates (the number of flies/person/year), in-
fective biting rates (the number of infective flies/person/
year), and transmission potentials (the number of infective
larvae/person/year)] and (3) impact of interventions on
prevalence, intensity and transmission of onchocerciasis
(measured by proportional changes in microfilarial preva-
lence and density between different data collection time-
points). The secondary outcomes will be environmental
and socio-demographic factors supporting the primary out-
comes (evaluated through meta-regression in the first
instance and subsequently through spatial statistics tech-
niques as described below).
Data analysis
Data will be recorded as point prevalence and/or mean
intensity of infection (the type of mean, arithmetic or
geometric, will also be recorded); uncertainty regarding
sampling sizes will be estimated by calculating 95% con-
fidence intervals for prevalence [16]. Since the distribu-
tion of the number of microfilariae per skin snip (or per
milligrams of skin) and the number of palpable nodules
per person is typically overdispersed among hosts, the
standard deviation (SD) for intensity of infection will not
be appropriate. However, when individual data are avail-
able, the distribution of these data will be ascertained
and appropriate measures of variance will be calculated.
For harmonization purposes, nodule prevalence will be
converted into microfilarial prevalence [17, 18], albeit
retaining information to allow identification of directly
measured or converted microfilarial prevalence esti-
mates. Prevalence and intensity of infection estimates
will be stratified according to gender, age, geographical
location and year of publication. Chi-square and the
non-parametric Mann-Whitney and Kruskal-Wallis tests
will be used to compare, between different data collec-
tion time points/periods, the prevalence and intensity of
O. volvulus infection, respectively. Random-effects meta-
analysis will be conducted. The I2 statistic will be used
to quantify heterogeneity, and tau-squared (τ2) will be
used to indicate the extent of between-study variance
[19]. Meta-regression will be used to identify covariates
influencing the estimates with the aim of identifying
models that best predict the variability of effect sizes (i.e.
that maximise maximum likelihood, minimise Akaike
Information Criterion and explain the highest percent-
age of the dependent variable variance) [20, 21]. Publica-
tion bias and sensitivity analyses will also be conducted.
(Publication bias can be assessed using funnel plots and
Egger’s regression asymmetry test [22, 23]. A trim-and-
fill technique to identify and correct the asymmetry in
funnel plots can also be applied [24].)
Data on prevalence and intensity of infection will be used
to draw thematic maps using a geographical information
system (GIS) software (ArcGIS, version 10.2, ESRI Inc.), ac-
cording to interventions and environmental characteristics.
Indeed, maps of interventions against onchocerciasis as well
as maps of different environmental parameters (climate,
vegetation, hydrography, soil … ) will be superimposed on
point prevalence and intensity of infection maps to eluci-
date the impact of these factors on onchocerciasis trends in
Cameroon. Kriging and/or model-based geostatistical
methods will then be used to obtain smooth prevalence
maps throughout the country [25, 26].
Assessment of risk of bias
The risk of bias of primary observational studies will be
evaluated using a methodological quality critical ap-
praisal checklist proposed in the Joanna Briggs Institute
(JBI) systematic review methods manual [27].
There might be a bias in the conversion of prevalence
of nodules to prevalence of microfilaridermia data since
the statistical relationship between these two types of
data is subject to a substantial amount of uncertainty. In
addition, studies that will not present data disaggregated
by community/village will not be included, likely leading
to a selection bias.
Confidence in cumulative evidence
The quality of the evidence will be judged using the Grad-
ing of Recommendations Assessment, Development and
Evaluation (GRADE) approach [28]. Evidence quality as-
sessment will be performed for each outcome. The grades
of evidence will be defined into four categories and adjudi-
cated as “high” (further research is unlikely to change our
confidence in the estimate of effect), “moderate” (further
research is likely to have an important impact on our con-
fidence in the estimate of effect and may change the esti-
mate), “low” (further research is very likely to have an
important impact on our confidence in the estimate of ef-
fect and is likely to change the estimate) and “very low”
(any estimate of effect is very uncertain) [28]. The confi-
dence in evidence will be discussed among authors, and a
narrative synthesis of the results will be provided as some
degree of heterogeneity will be expected.
Discussion
Onchocerciasis remains a public health problem, particu-
larly in Africa (including Cameroon) where 99% of the in-
fected population live. Despite control efforts through
MDA with ivermectin, vector control and recent interven-
tion trials of anti-Wolbachia doxycycline therapy, the
infection still persists, with unexpected high prevalence in
certain areas [6]. Indeed, it has been suggested, using
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epidemiological models, that onchocerciasis may not be
eliminated before 2030 if interventions rely solely on iver-
mectin MDA [7–9, 29]. This systematic review will evalu-
ate onchocerciasis epidemiological trends in association
with environmental characteristics and control interven-
tions in Cameroon. The outcomes of this systematic re-
view will directly inform both programme managers and
policymakers of available data and data needs. This will
change the approach towards elimination of onchocerciasis
in Cameroon by highlighting and characterising the vari-
ous epidemiological scenarios that must be considered, the
impact of current interventions and the need for tailored
ATS. Based on a better understanding of the factors
underlying spatiotemporal trends in onchocerciasis preva-
lence, intensity and transmission at ecologically appropri-
ate scales (foci, river basins, community clusters), suitable
combinations of alternative and complementary interven-
tion strategies [11] will be defined to help accelerate on-
chocerciasis elimination wherever it is still endemic.
The main limitations of this systematic review will be
(1) the access to unpublished data, or to more detailed
information when data will be too aggregated, and (2) the
discrepancies between collection and reporting of infor-
mation by different authors. To overcome this situation,
study authors of primary publications and/or collaborators
will be contacted to collect additional information.
Amendments to protocol
After approval and publication of the protocol, any amend-
ments, if necessary, will be registered with PROSPERO and
documented in the final publication. The date of each
amendment as well as a description and rationale of each
change made when publishing the review will be provided.
Dissemination
This systematic review will be conducted as part of a PhD
thesis. The results of this systematic review will be published
in international peer-reviewed journals and disseminated to
the research community, programme managers, policy-
makers and stakeholders through presentations at scientific
and other meetings, via social media and mass media.
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